Parnax Lab

Parnax Lab FCF/Net Income

The Free Cash Flow to Net Income Ratio of Parnax Lab (506128.BO) as of Nov 14, 2026 is 119.14 %. In the previous year, Free Cash Flow to Net Income Ratio was -172.93 % — a change of -168.89% (higher).

FCF/Net Income

119.14 %

YoY

-168.89%

Last updated:

Free Cash Flow to Net Income Ratio of Parnax Lab is 2025 119.14 % . Free Cash Flow to Net Income Ratio of Parnax Lab was 2024 -172.93 % . It decreases by -168.89% higher compared to the previous year.

The Parnax Lab FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
726.18 INR
Jan 1, 2019
-78.97 INR
Jan 1, 2020
152.21 INR
Jan 1, 2021
63.52 INR
Jan 1, 2022
-112.61 INR
Jan 1, 2023
111.74 INR
Jan 1, 2024
-172.93 INR
Jan 1, 2025
119.14 INR
The Parnax Lab FCF/Net Income history
YEARFCF/Net IncomeYoY
119.14 %-168.89%
-172.93 %-254.77%
111.74 %-199.23%
-112.61 %-277.28%
63.52 %-58.27%
152.21 %-292.75%
-78.97 %-110.87%
726.18 %+3,588.37%
19.69 %-118.67%
-105.47 %+10.97%
-95.04 %-59.05%
-232.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Free Cash Flow to Net Income Ratio of Parnax Lab is 119.14 % in 2025.

Free Cash Flow to Net Income Ratio of Parnax Lab changed from -172.93 % to 119.14 %, representing a -168.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Parnax Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Parnax Lab

All Key Metrics — Parnax Lab